Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2008 Aug 5;99(3):448-54.
doi: 10.1038/sj.bjc.6604497.

The clinical implications of sunitinib-induced hypothyroidism: a prospective evaluation

P Wolter  1 , C Stefan, B Decallonne, H Dumez, M Bex, P Carmeliet, P Schöffski
Affiliations

The clinical implications of sunitinib-induced hypothyroidism: a prospective evaluation

P Wolter et al. Br J Cancer. .

Abstract

Sunitinib is approved for the treatment of metastatic renal cell carcinoma (RCC) and imatinib-resistant or -intolerant gastrointestinal stromal tumours (GIST). Several studies have identified unexpected rates of thyroid dysfunction with sunitinib treatment. We performed a prospective observational study with the aim of more accurately defining the incidence and severity of hypothyroidism in RCC or GIST patients receiving sunitinib. Thyroid function was assessed at baseline and on days 1 and 28 of each treatment cycle. Thyroid antibodies were assessed at baseline and during follow-up if abnormal thyroid function tests were recorded. Sixteen patients (27%) developed sub- or clinical hypothyroidism and required hormone replacement and 20 patients (34%) showed at least one elevated thyroid-stimulating hormone not requiring therapeutic intervention. Twenty patients (34%) did not develop any biochemical thyroid abnormality. Thus, sunitinib can induce (sub-) clinical hypothyroidism, warranting close monitoring of thyroid function. We propose a new algorithm for managing this side effect in clinical practise.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Representative courses of TSH (mIU l−1) in three patients receiving sunitinib (A–C); median TSH during first cycles of sunitinib treatment based on severity of thyroid dysfunction (D).
Figure 2
Figure 2
Proposed algorithm to diagnose and treat thyroid dysfunction during sunitinib treatment.
See this image and copyright information in PMC

References

    1. Baffert F, Le T, Sennino B, Thurston G, Kuo CJ, Hu-Lowe D, McDonald DM (2006) Cellular changes in normal blood capillaries undergoing regression after inhibition of VEGF signaling. Am J Physiol Heart Circ Physiol 290: H547–H559 - PubMed
    1. Burstein HJ, Elias AD, Rugo HS, Cobleigh MA, Wolff AC, Eisenberg PD, Lehman M, Adams BJ, Bello CL, De Primo SE, Miller KD (2008) Phase II study of sunitinib malate, an oral multitargeted tyrosine kinase inhibitor, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane. J Clin Oncol 26: 1810–1816 - PubMed
    1. Chow LQ, Eckhardt SG (2007) Sunitinib: from rational design to clinical efficacy. J Clin Oncol 25: 884–896 - PubMed
    1. de Groot JW, Links TP, van der Graaf WT (2006) Tyrosine kinase inhibitors causing hypothyroidism in a patient on levothyroxine. Ann Oncol 17: 1719–1720 - PubMed
    1. Demers LM (2004) Thyroid disease: pathophysiology and diagnosis. Clin Lab Med 24: 19–28 - PubMed

Publication types

MeSH terms